Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HOW TO PLAY IT: Wading back into European equities

Fri, 18th Jan 2013 18:42

By David Randall

NEW YORK, Jan 18(Reuters) - After more than three years ofcrisis, Europe's days as a no-man's land may be coming to anend.

The Euro Stoxx 50, an index of blue chip European stocks, isup more than 30 percent as of Thursday from the low it hit onJune 1. It gained a total of 11.2 percent in 2012.

Driving this rally is the pledge by the European CentralBank to support the euro by any means necessary. It lowered therisk that Greece would leave the euro zone and potentially breakup the currency union, and drove bond yields in Spain down fromcrisis levels.

With fears of a worst-case scenario subsiding, institutionalinvestors have been increasing their allocations to Europeanstocks, according to a Bank of America Merrill Lynch surveypublished Tuesday.

Analysts and portfolio managers say that the push is moreakin to wading back into the pool than taking a full dive. Withan unemployment rate of 11.8 percent and an economy that shrunkby 0.1 percent in its most recent quarter, this may be a time tocautiously add exposure to the euro zone, rather than try tochase the market.

Here are ways these U.S. fund managers and financialadvisers are increasing stakes in Europe.

BUYING SELECTIVELY

Even after the market's 2012 rebound, financial andindustrial stocks look attractive on a valuation basis, saidChad Deakins, portfolio manager of the $280 million RidgeWorthInternational Equity fund. Deakins has about 65percent of his assets in European stocks now, compared with lessthan 60 percent at the beginning of last year.

Deakins is focusing most of his portfolio on Germany andFrance, but maintains that it's still too early to increaseexposure to companies in Spain, Portugal or Ireland, which havehigher unemployment rates and financially strapped governments.

Among his picks: French bank BNP Paribas SA andAustrian bank Raiffeisen Bank International AG, bothof which trade at price to book ratios of 0.73 or below and forless than 9 times earnings. Deakins says each bank should tradeat 1.5 times book value.

Raiffeisen has particularly attractive growth prospectsbecause it makes loans in emerging European markets like Poland,he said. The company is already up 6.1 percent for the year, andcomes with a dividend yield of 3.1 percent.

Deakins has also been buying shares of industrial companiesthat have exposure to emerging markets like China and India,such as German chemical company BASF, Frenchtire-maker Michelin, and French energy company TotalSA.

Other fund managers are eschewing European industrialcompanies for pharmaceutical, telecom and utilities stocks thathaven't rallied as sharply as financials and consumer stocks.

"The volatility in Europe over the 12-month period createdvery good entry prices," said Suzanne Hutchins, a portfoliomanager of the $81 million Dreyfus Global Real Return fund.

Hutchins, who recently increased her stake in Europe to 19percent of assets from 13 percent of assets in April as part ofa global increase in riskier securities, is focusing oncompanies with large dividends and strong cash flows. Among herlarger positions: British pharmaceutical GlaxoSmithKline PLC, Swiss biotech Roche Holding AG, and Frenchpharma company Sanofi. Roche, for instance, offers adividend yield of 3.4 percent and is up 23.7 percent over thelast year through Thursday.

FUND OPTIONS

Some financial advisers are opting for funds over individualsecurities. Tony Zabigeala, vice president at Strategic WealthPartners in Seven Hills, Ohio, recently increased his stake inEurope to 25 percent of assets from 10 percent of assets.

Zabigeala invests in Europe mainly through the SPDR EuroStoxx 50 ETF (FEZ), a $1.4 billion fund that costs 29 cents per$100 invested and yields 3.7 percent.

"We expect to see a leadership change from U.S. equities toeurozone stocks this year," Zabigeala said.

Investors in the fund should note that it excludes holdingsin the U.K. and Switzerland, which "magnifies its exposure tothe weakest members of the euro zone, including Italy andSpain", noted Alex Bryan, a fund analyst at Morningstar.

Another euro bull is Will McGough, vice president ofportfolio management at Stadion Money Management. McGough loadedup on European stocks, boosting his fund's exposure to 21percent of assets from 4.9 percent of assets in the $13.5million Stadion Olympus Fund between April andDecember. The fund, which aims to follow market momentum, holdsa basket of ETFs instead of individual shares.

McCough has been buying shares of the $4.1 billion iSharesMSCI Germany ETF (EWG), targeting exporters that benefit fromemerging market growth and the U.S. economy. It costs 53 centsper $100 invested and yields 2.3 percent. The fund is up 24.6percent over the last year, according to Morningstar.

"Basically last year Europe went into a bear market in thefirst half of the year, and we're still seeing the recovery fromthat," McCough said.

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.